Navigation Links
Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment
Date:4/23/2014

The research, published in the journal Oncotarget, explored tumour heterogeneity where different cells have different appearances or their own DNA signatures within the same cancer. Such differences could make it difficult to design effective, targeted treatment strategies.

Firstly they confirmed the mutual exclusivity between the EGFR mutation and either the KRAS or BRAF mutation. Secondly, they found that lung cancers driven by the EGFR gene mutation have that specific mutation present uniformly throughout the tumour, regardless of microscopic appearance. In stark contrast, they discovered that some tumours, with either KRAS or BRAF gene mutations, do not have the mutation present in all parts of the tumour.


Lead researcher Associate Professor Gavin Wright from the University of Melbourne and Director of Surgical Oncology at St Vincent's Hospital, said the findings are good news for patients whose tumours contain treatable mutations in the EGFR gene.

Lung adenocarcinomas (the most common form of lung cancer) that feature the EGFR gene mutation tend to occur in women and non-smokers. They are very effectively treated by the oral drug gefitinib, so it is vital that this mutation is accurately detected.

"Because we found that this particular EGFR mutation was present throughout all areas of such tumours tested, patients with this mutation will be easily identified, even by small needle biopsies."

"This means they will always be offered the appropriate targeted treatment drug, which is more effective than standard chemotherapy for these cases," he said.

"Fortunately, the diagnostic accuracy for biopsies of lung cancers with this mutation is only dependent on there being sufficient tumour cells for testing."

The story is a little more complicated for other lung cancers, though. The researchers found that two less common mutations KRAS and BRAF - could be missed in small biopsy sample
'/>"/>

Contact: Liz Banks-Anderson
banks@unimelb.edu.au
61-383-444-362
University of Melbourne
Source:Eurekalert

Page: 1 2

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Head, Body Lice Are Genetically Very Similar
4. Certain Genetic Regions May Be Tied to Osteoporosis
5. Study of half siblings provides genetic clues to autism
6. Genetic variants, tobacco exposure and lung cancer risk
7. Research Gets Closer to Genetic Roots of Glaucoma
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
10. Some women may be genetically predisposed to smoking-related hot flashes
11. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... York (PRWEB) January 22, 2015 Thousand ... Fresenius Medical Care recalled its GranuFlo and NaturaLyte dialysis ... litigation underway in U.S. District Court, District of Massachusetts, ... January 20th, the Court has remanded a case filed ...
(Date:1/22/2015)... has released a new blog post presenting the basic features ... Purchasing an accidental death and dismemberment rider for a car ... provides benefits if the insured dies in an accident. Accidental ... life insurance. , AD&D is not expensive and can ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... NAPA, Calif., April 15 Senetek PLC (OTC,Bulletin Board: ... technologies that target the science of healthy aging, announced ... 2007., Revenue for the year ended December 31, ... for the fourth quarter of 2007,were $223,000, compared with ...
... 15 The Joint Center for,Political and Economic ... of health in order to reduce disparities and ... linked to,socioeconomic status," said Ralph B. Everett, the ... determinants, most health,inequities are avoidable," he added., ...
... a new study to evaluate the impact of a ... Presented at the American Association of Cancer Research Annual ... tracking system is key to improving rates of medical ... eliminating racial disparity in treatment. , Women who ...
... many with the autoimmune disease, researchers say , , TUESDAY, April ... the number of attacks in people with multiple sclerosis appears ... The pill was effective in preventing relapses in more than ... years, according to research that was expected to be presented ...
... Council (ACC) supports the rigorous scientific evaluation process,of ... Evaluation of,Risks to Human Reproduction. Following an expert ... NTP Brief on bisphenol A affirms that,there are ... effects of,bisphenol A on human reproduction and development., ...
... their names to ghost-written studies that exaggerated painkiller,s ... Industry documents reveal that pharmaceutical giant Merck & ... Vioxx research published in top medical journals while ... controversial cox-2 painkiller. , The company apparently also ...
Cached Medicine News:Health News:Senetek PLC Reports 2007 Financial Results 2Health News:Senetek PLC Reports 2007 Financial Results 3Health News:Joint Center Sees Social Determinants of Health as Key to Reducing Disparities at Annual Fund-raising Gala 2Health News:Tracking and feedback registry helps reduce disparities in breast cancer care 2Health News:Pill Reduces Relapses in MS Patients 2Health News:Draft National Toxicology Program Report Supports Safety of Bisphenol A 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 3Health News:Key Vioxx Research Was Written by Merck, Documents Allege 4
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today reported financial results ... Global revenue for the Company,s Urgent ® ... new quarterly revenue record, as compared to $3.9 million ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... internal candidate to enter Phase 2 clinical development, ... PCOP ), an innovator in the discovery and ... initiation of a Phase 2a,clinical study of PS433540, ... dual-acting angiotensin and endothelin receptor antagonist,(DARA) that is ...
... in Normal Volunteers, BERKELEY HEIGHTS, N.J., Sept. 17 ... Food and Drug Administration (FDA) has,allowed the Investigational New ... its new drug known as G4544. In addition, Genta ... has been treated,with single doses of G4544 without experiencing ...
Cached Medicine Technology:Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease 2Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease 3Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease 4
... is an immunochromatography based one step ... qualitative determination of Methamphetamine in human ... 1000 ng/mL. This assay has not ... care,location and is for use by ...
... a qualitative immunoassay intended to ... usage of cocaine by detecting ... in human urine at a ... It is for health care,professional ...
... Biosystems introduced the completely automated, 16-capillary ... Genetic Analyzer.,Now the innovative technology of ... our new four-capillary ABI PRISM 3100-Avant ... needs, the fully automated 3100-Avant system ...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Medicine Products: